DIM BioConvergence for Health – Call for projects 2024 / Doctoral grants in Biotherapy, Bioproduction, Synthetic Biology
BioConvergence for Health (BioConvS) is a “Major Research and Innovation Domain” (DIM) initiative of the Ile-de-France Region which aims to structure the communities of synthetic biology, biotherapy and bioproduction, to support the transition from scientific excellence to innovation, and position the Île-de-France region as an international reference in the field.
BioConvS is led by Université Paris Cité in partnership with Sorbonne Université, Institut Curie - PSL, Institut Micalis (INRAe, AgroParisTech, Université Paris Saclay), INSERM, Généthon, Génopole and other partners. BioConvS brings together actors from the public and private sectors and benefits from €12.5 million in support from the Ile-de-France Region. More details on the DIM BioConvS at: https://bioconvs.org/
About the call
This call will finance four doctoral grants on projects linked to one of the themes of the DIM BioConvS:
Life sciences engineering and bioproduction
Development of evidence of therapeutic principles
New high-throughput and standardizable analytical methods
Digital or AI tools to improve data analysis or modeling in quality control and production methods
Guarantee an inclusive, responsible and sustainable Bioconvergence
It is open from February 12 to April 22, 2024. Only theses supervised by at least two teams (the second team can be a company) located in Ile-de-France are eligible for this call.
Additional teams can participate in the project to provide additional specific expertise without geographical limitation. Teams outside the Ile-de-France region will not be funded.
As indicated above, start-ups and companies from the Ile-de-France region can also be associated with the project but will not be funded as part of this call. Participation in a company’s project will be a plus.
Projects must be written in English, but a summary in French is required.
Loading... 
